{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:00:50Z","timestamp":1777111250311,"version":"3.51.4"},"reference-count":344,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":2315,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,15]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendations on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-susceptible TB.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Published systematic reviews, meta-analyses, and a new individual patient data meta-analysis from 12,030 patients, in 50 studies, across 25 countries with confirmed pulmonary rifampin-resistant TB were used for this guideline. Meta-analytic approaches included propensity score matching to reduce confounding. Each recommendation was discussed by an expert committee, screened for conflicts of interest, according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Twenty-one Population, Intervention, Comparator, and Outcomes questions were addressed, generating 25 GRADE-based recommendations. Certainty in the evidence was judged to be very low, because the data came from observational studies with significant loss to follow-up and imbalance in background regimens between comparator groups. Good practices in the management of MDR-TB are described. On the basis of the evidence review, a clinical strategy tool for building a treatment regimen for MDR-TB is also provided.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n New recommendations are made for the choice and number of drugs in a regimen, the duration of intensive and continuation phases, and the role of injectable drugs for MDR-TB. On the basis of these recommendations, an effective all-oral regimen for MDR-TB can be assembled. Recommendations are also provided on the role of surgery in treatment of MDR-TB and for treatment of contacts exposed to MDR-TB and treatment of isoniazid-resistant TB.<\/jats:p>\n <\/jats:sec>","DOI":"10.1164\/rccm.201909-1874st","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T10:27:03Z","timestamp":1573813623000},"page":"e93-e142","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":374,"title":["Treatment of Drug-Resistant Tuberculosis. An Official ATS\/CDC\/ERS\/IDSA Clinical Practice Guideline"],"prefix":"10.1093","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-1311","authenticated-orcid":false,"given":"Payam","family":"Nahid","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-0637","authenticated-orcid":false,"given":"Sundari R.","family":"Mase","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-574X","authenticated-orcid":false,"given":"Giovanni Battista","family":"Migliori","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1600-4474","authenticated-orcid":false,"given":"Giovanni","family":"Sotgiu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-8547","authenticated-orcid":false,"given":"Graham H.","family":"Bothamley","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3122-0773","authenticated-orcid":false,"given":"Jan L.","family":"Brozek","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-2601","authenticated-orcid":false,"given":"Adithya","family":"Cattamanchi","sequence":"additional","affiliation":[]},{"given":"J. Peter","family":"Cegielski","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-0111","authenticated-orcid":false,"given":"Lisa","family":"Chen","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3324-926X","authenticated-orcid":false,"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[]},{"given":"Tracy L.","family":"Dalton","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Federica","family":"Fregonese","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-7895","authenticated-orcid":false,"suffix":"Jr.","given":"C. Robert","family":"Horsburgh","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-8734","authenticated-orcid":false,"given":"Faiz","family":"Ahmad Khan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4192-5080","authenticated-orcid":false,"given":"Fayez","family":"Kheir","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5519-2474","authenticated-orcid":false,"given":"Zhiyi","family":"Lan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3273-1097","authenticated-orcid":false,"given":"Alfred","family":"Lardizabal","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-4185","authenticated-orcid":false,"given":"Michael","family":"Lauzardo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6770-086X","authenticated-orcid":false,"given":"Joan M.","family":"Mangan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3024-1940","authenticated-orcid":false,"given":"Suzanne M.","family":"Marks","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-0835","authenticated-orcid":false,"given":"Lindsay","family":"McKenna","sequence":"additional","affiliation":[]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3455-658X","authenticated-orcid":false,"given":"Carole D.","family":"Mitnick","sequence":"additional","affiliation":[]},{"given":"Diana M.","family":"Nilsen","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1211-5043","authenticated-orcid":false,"given":"Farah","family":"Parvez","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-7052","authenticated-orcid":false,"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[]},{"given":"Ann","family":"Raftery","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-4133","authenticated-orcid":false,"given":"H. Simon","family":"Schaaf","sequence":"additional","affiliation":[]},{"given":"Neha S.","family":"Shah","sequence":"additional","affiliation":[]},{"given":"Jeffrey R.","family":"Starke","sequence":"additional","affiliation":[]},{"given":"John W.","family":"Wilson","sequence":"additional","affiliation":[]},{"given":"Jonathan M.","family":"Wortham","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7722-0958","authenticated-orcid":false,"given":"Terence","family":"Chorba","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2922-4940","authenticated-orcid":false,"given":"Barbara","family":"Seaworth","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"2026030321351417000_bib1","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib2","article-title":"FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"2026030321351417000_bib3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment\u20132017. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"2026030321351417000_bib4","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026030321351417000_bib5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/rccm.200602-197ST","article-title":"An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations","volume":"174","author":"Sch\u00fcnemann","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1590\/s1806-37562018000000279","article-title":"Global TB Network: working together to eliminate tuberculosis","volume":"44","author":"Silva","year":"2018","journal-title":"J Bras Pneumol"},{"key":"2026030321351417000_bib7","article-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019"},{"key":"2026030321351417000_bib8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib9","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1183\/09031936.00198813","article-title":"Tuberculosis elimination: theory and practice in Europe","volume":"43","author":"D\u2019Ambrosio","year":"2014","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1183\/09031936.00214014","article-title":"Towards tuberculosis elimination: an action framework for low-incidence countries","volume":"45","author":"L\u00f6nnroth","year":"2015","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib11","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib12","article-title":"Global tuberculosis report 2018","author":"World Health Organization","year":"2018"},{"key":"2026030321351417000_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib14","article-title":"Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018","edition":"3rd ed"},{"key":"2026030321351417000_bib15"},{"key":"2026030321351417000_bib16","article-title":"Drug-resistant tuberculosis: a survival guide for clinicians","author":"Curry International Tuberculosis Center and California Department of Public Health","year":"2016","edition":"3rd ed"},{"key":"2026030321351417000_bib17","article-title":"Management of multidrug-resistant tuberculosis in children: a field guide","author":"Sentinel Project on Pediatric Drug-Resistant Tuberculosis","year":"2019","edition":"4th ed"},{"key":"2026030321351417000_bib18","article-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization","year":"2014"},{"key":"2026030321351417000_bib19","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1183\/13993003.00462-2016","article-title":"Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method","volume":"48","author":"Mitnick","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib20","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1164\/rccm.2508001","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: controlling tuberculosis in the United States","volume":"172","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib21","article-title":"Who policy on TB infection control in health-care facilities, congregate settings and households","volume-title":"Switzerland","author":"World Health Organization","year":"2009"},{"key":"2026030321351417000_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.rmed.2017.09.007","article-title":"Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug\/extensively-resistant tuberculosis (M\/XDR-TB) in Europe: a tuberculosis network European Trialsgroup (TBNET) study","volume":"132","author":"Bothamley","year":"2017","journal-title":"Respir Med"},{"key":"2026030321351417000_bib23","article-title":"Who treatment guidelines for drug-resistant tuberculosis 2016 update","author":"World Health Organization","year":"2016"},{"key":"2026030321351417000_bib24","doi-asserted-by":"crossref","first-page":"1900391","DOI":"10.1183\/13993003.00391-2019","article-title":"Reducing tuberculosis transmission: a consensus document from the world health organization regional office for Europe","volume":"53","author":"Migliori","year":"2019","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1017\/S0950268817003041","article-title":"Risk factors for infectiousness of patients with tuberculosis: a systematic review and meta-analysis","volume":"146","author":"Melsew","year":"2018","journal-title":"Epidemiol Infect"},{"key":"2026030321351417000_bib26","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.5588\/ijtld.13.0834","article-title":"Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis","volume":"18","author":"Dharmadhikari","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib27","first-page":"1","article-title":"Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005","volume":"54","author":"Jensen","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"2026030321351417000_bib28","article-title":"Standards of practice for case management","author":"Case Management Society of America","year":"2016"},{"key":"2026030321351417000_bib29","volume-title":"Outpatient case management for adults with medical illness and complex care needs.","author":"Hickam","year":"2013"},{"key":"2026030321351417000_bib30","volume-title":"Case management: what is it and how it can best be implemented.","author":"Ross","year":"2011"},{"key":"2026030321351417000_bib31","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0196-6553(98)70027-6","article-title":"Tuberculosis control in the New York State Department of Correctional Services: a case management approach","volume":"26","author":"Klopf","year":"1998","journal-title":"Am J Infect Control"},{"key":"2026030321351417000_bib32","first-page":"1","article-title":"Advisory Council for the Elimination of Tuberculosis. Essential components of a tuberculosis prevention and control program: recommendations of the Advisory Council for the Elimination of Tuberculosis","volume":"44","year":"1995","journal-title":"MMWR Recomm Rep"},{"key":"2026030321351417000_bib33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1370\/afm.1239","article-title":"The values and value of patient-centered care","volume":"9","author":"Epstein","year":"2011","journal-title":"Ann Fam Med"},{"key":"2026030321351417000_bib34","doi-asserted-by":"crossref","first-page":"1702678","DOI":"10.1183\/13993003.02678-2017","article-title":"ERS\/ECDC Statement: European Union standards for tuberculosis care, 2017 update","volume":"51","author":"Migliori","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib35","article-title":"International standards for tuberculosis care","author":"TB CARE I","year":"2018","edition":"3rd ed"},{"key":"2026030321351417000_bib36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1745-7599.2008.00360.x","article-title":"Patient-centered care and adherence: definitions and applications to improve outcomes","volume":"20","author":"Robinson","year":"2008","journal-title":"J Am Acad Nurse Pract"},{"key":"2026030321351417000_bib37","volume-title":"Tuberculosis nursing: a comprehensive guide to patient care","author":"National Tuberculosis Controllers Association","year":"2011","edition":"2nd ed."},{"key":"2026030321351417000_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0891-5520(03)00047-3","article-title":"Multidrug-resistant tuberculosis","volume":"16","author":"Seaworth","year":"2002","journal-title":"Infect Dis Clin North Am"},{"key":"2026030321351417000_bib39","doi-asserted-by":"crossref","first-page":"e1002595","DOI":"10.1371\/journal.pmed.1002595","article-title":"Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies","volume":"15","author":"Alipanah","year":"2018","journal-title":"PLoS Med"},{"key":"2026030321351417000_bib40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.5588\/ijtld.17.0596","article-title":"Interventions to improve adherence to tuberculosis treatment: systematic review and meta-analysis","volume":"22","author":"M\u00fcller","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1183\/13993003.00424-2016","article-title":"Digital health for the End TB Strategy: developing priority products and making them work","volume":"48","author":"Falzon","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib42","doi-asserted-by":"crossref","first-page":"1602049","DOI":"10.1183\/13993003.02049-2016","article-title":"Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience","volume":"49","author":"Sinkou","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib43","doi-asserted-by":"crossref","first-page":"588","DOI":"10.5588\/ijtld.15.0738","article-title":"Enhancing management of tuberculosis treatment with video directly observed therapy in New York City","volume":"20","author":"Chuck","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib44","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3201\/eid2203.151620","article-title":"Monitoring therapy compliance of tuberculosis patients by using video-enabled electronic devices","volume":"22","author":"Story","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2026030321351417000_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7309\/jmtm.5.2.3","article-title":"A qualitative study exploring stakeholder perceptions of video directly observed therapy for monitoring tuberculosis treatment in the US-Mexico border region","volume":"5","author":"Z\u00fa\u00f1iga","year":"2016","journal-title":"J Mob Technol Med"},{"key":"2026030321351417000_bib46","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.5588\/ijtld.14.0923","article-title":"Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study","volume":"19","author":"Garfein","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib47","article-title":"Digital health for the End TB Strategy: an agenda for action","author":"World Health Organization","year":"2015"},{"key":"2026030321351417000_bib48","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5588\/pha.15.0047","article-title":"Setting priorities for a research agenda to combat drug-resistant tuberculosis in children","volume":"5","author":"Velayutham","year":"2015","journal-title":"Public Health Action"},{"key":"2026030321351417000_bib49","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3201\/eid2410.180459","article-title":"Tuberculosis treatment monitoring by video directly observed therapy in 5 health districts, California, USA","volume":"24","author":"Garfein","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2026030321351417000_bib50","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026030321351417000_bib51","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(18)30329-1","article-title":"Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis","volume":"6","author":"Seddon","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026030321351417000_bib52","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMc1603274","article-title":"Treatment outcomes in multidrug-resistant tuberculosis","volume":"375","author":"G\u00fcnther","year":"2016","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM199302253280802","article-title":"Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin","volume":"328","author":"Goble","year":"1993","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib54","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1183\/09031936.00073611","article-title":"WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update","volume":"38","author":"Falzon","year":"2011","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib55","article-title":"Guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization","year":"2008"},{"key":"2026030321351417000_bib56","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026030321351417000_bib57","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat Med"},{"key":"2026030321351417000_bib58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1164\/arrd.1965.91.1.117","article-title":"The nature of mycobacterial penicillinase","volume":"91","author":"Kasik","year":"1965","journal-title":"Am Rev Respir Dis"},{"key":"2026030321351417000_bib59","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/1469-0691.12335","article-title":"Salvage therapy for multidrug-resistant tuberculosis","volume":"20","author":"Seung","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2026030321351417000_bib60","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/00365540152029954","article-title":"Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis","volume":"33","author":"Donald","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"2026030321351417000_bib61","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1086\/513945","article-title":"Activity of amoxicillin\/clavulanate in patients with tuberculosis","volume":"26","author":"Chambers","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib62","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1378\/chest.99.4.1025","article-title":"Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis","volume":"99","author":"Nadler","year":"1991","journal-title":"Chest"},{"key":"2026030321351417000_bib63","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/jac\/dks395","article-title":"Is there a place for \u03b2-lactams in the treatment of multidrug-resistant\/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin\/clavulanate","volume":"68","author":"Gonzalo","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026030321351417000_bib64","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/INF.0b013e3182154b05","article-title":"Meropenem\/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis","volume":"30","author":"Dauby","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2026030321351417000_bib65","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/ijms17030373","article-title":"Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review","volume":"17","author":"Sotgiu","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2026030321351417000_bib66","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1183\/13993003.02146-2015","article-title":"Effectiveness and safety of meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"Tiberi","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib67","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/09031936.00124312","article-title":"Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB","volume":"41","author":"De Lorenzo","year":"2013","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib68","doi-asserted-by":"crossref","first-page":"474","DOI":"10.5588\/ijtld.15.0666","article-title":"Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications","volume":"20","author":"Swaminathan","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib69","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1128\/AAC.02020-12","article-title":"Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate","volume":"57","author":"Ahmed","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib70","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1503\/cmaj.140848","article-title":"Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication","volume":"187","author":"Gillies","year":"2015","journal-title":"CMAJ"},{"key":"2026030321351417000_bib71","first-page":"1","article-title":"Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis","volume":"62","author":"Mase","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"2026030321351417000_bib72","author":"U.S. Food and Drug Administration"},{"key":"2026030321351417000_bib73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"2026030321351417000_bib74","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1128\/AAC.00753-16","article-title":"Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in mycobacterium tuberculosis","volume":"60","author":"Almeida","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib75","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline resistance: its emergence, mechanism, and prevention","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib76","first-page":"66","article-title":"Bedaquiline (Sirturo) for multidrug-resistant tuberculosis","volume":"55","year":"2013","journal-title":"Med Lett Drugs Ther"},{"key":"2026030321351417000_bib77","doi-asserted-by":"crossref","first-page":"1700146","DOI":"10.1183\/13993003.00146-2017","article-title":"Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline","volume":"49","author":"Pontali","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib78","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/13993003.01891-2015","article-title":"Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence","volume":"47","author":"Pontali","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib79","article-title":"Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB)","author":"World Health Organization","year":"2018"},{"key":"2026030321351417000_bib80","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib81","doi-asserted-by":"crossref","first-page":"1701462","DOI":"10.1183\/13993003.01462-2017","article-title":"Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence","volume":"50","author":"Pontali","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib82","doi-asserted-by":"crossref","DOI":"10.3201\/eid2310.170303","article-title":"Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis","volume":"23","author":"Achar","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2026030321351417000_bib83","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1164\/rccm.201606-1227CI","article-title":"New and repurposed drugs for pediatric multidrug-resistant tuberculosis: practice-based recommendations","volume":"195","author":"Harausz","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib84","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1183\/13993003.01980-2015","article-title":"First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB","volume":"47","author":"Lewis","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib85","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1128\/AAC.05690-11","article-title":"Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo","volume":"56","author":"England","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib86","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis","volume":"323","author":"Hugonnet","year":"2009","journal-title":"Science"},{"key":"2026030321351417000_bib87","doi-asserted-by":"crossref","first-page":"1600993","DOI":"10.1183\/13993003.00993-2016","article-title":"Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis","volume":"49","author":"Fox","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib88","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/17512433.2016.1208562","article-title":"An update on repurposed medications for the treatment of drug-resistant tuberculosis","volume":"9","author":"Mafukidze","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026030321351417000_bib89","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/cid\/ciw088","article-title":"Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"62","author":"Tiberi","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib90","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1183\/13993003.00214-2016","article-title":"Comparison of effectiveness and safety of imipenem\/clavulanate- versus meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"Tiberi","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib91","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1183\/13993003.01654-2015","article-title":"Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis","volume":"47","author":"van Rijn","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib92","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1183\/13993003.01278-2015","article-title":"Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience","volume":"47","author":"Tiberi","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib93","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1183\/13993003.01249-2016","article-title":"Faster for less: the new \u201cshorter\u201d regimen for multidrug-resistant tuberculosis","volume":"48","author":"Sotgiu","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib94","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/civ027","article-title":"Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China","volume":"60","author":"Tang","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib95","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","article-title":"Systematic review of clofazimine for the treatment of drug-resistant tuberculosis","volume":"17","author":"Gopal","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib96","doi-asserted-by":"crossref","first-page":"1602308","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib97","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1164\/rccm.201304-0753OC","article-title":"Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice","volume":"188","author":"Grosset","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib98","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1128\/AAC.00395-15","article-title":"Mode of action of clofazimine and combination therapy with benzothiazinones against mycobacterium tuberculosis","volume":"59","author":"Lechartier","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib99","doi-asserted-by":"crossref","first-page":"e004143","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"key":"2026030321351417000_bib100","article-title":"Position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage 1 preliminary results","author":"World Health Organization","year":"2018"},{"key":"2026030321351417000_bib101","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.00079413","article-title":"Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation","volume":"43","author":"Diel","year":"2014","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib102","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20189-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib103","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib104","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"Piubello","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib106","doi-asserted-by":"crossref","first-page":"1601967","DOI":"10.1183\/13993003.01967-2016","article-title":"Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country","volume":"49","author":"Javaid","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib107","doi-asserted-by":"crossref","first-page":"1601992","DOI":"10.1183\/13993003.01992-2016","article-title":"Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union","volume":"49","author":"van der Werf","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib108","doi-asserted-by":"crossref","first-page":"1602309","DOI":"10.1183\/13993003.02309-2016","article-title":"Resistance profile of drugs composing the \u201cshorter\u201d regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015","volume":"49","author":"Dalcolmo","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib109","doi-asserted-by":"crossref","first-page":"1602445","DOI":"10.1183\/13993003.02445-2016","article-title":"Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil","volume":"49","author":"Dalcolmo","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib110","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1183\/13993003.01552-2016","article-title":"Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib111","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1183\/13993003.01207-2016","article-title":"Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine","volume":"48","author":"Wallis","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib112","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","article-title":"Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline","volume":"191","author":"Diacon","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib113","doi-asserted-by":"crossref","first-page":"e1002591","DOI":"10.1371\/journal.pmed.1002591","article-title":"Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis","volume":"15","author":"Harausz","year":"2018","journal-title":"PLoS Med"},{"key":"2026030321351417000_bib114","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-3156.2008.02045.x","article-title":"International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results","volume":"13","author":"Kroger","year":"2008","journal-title":"Trop Med Int Health"},{"key":"2026030321351417000_bib115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/17512433.2018.1421067","article-title":"Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children","volume":"11","author":"Schaaf","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026030321351417000_bib116","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/AAC.00558-10","article-title":"Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine","volume":"55","author":"Bruning","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1472-9792(08)70007-6","article-title":"Cycloserine","volume":"88","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"2026030321351417000_bib118","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.5588\/ijtld.12.0863","article-title":"Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis","volume":"17","author":"Hwang","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib119","doi-asserted-by":"crossref","first-page":"e02410-17","DOI":"10.1128\/AAC.02410-17","article-title":"Pharmacokinetics of second-line antituberculosis drugs in children with multidrug-resistant tuberculosis in India","volume":"62","author":"Hemanth Kumar","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","article-title":"Safety and tolerability profile of second-line anti-tuberculosis medications","volume":"38","author":"Ramachandran","year":"2015","journal-title":"Drug Saf"},{"key":"2026030321351417000_bib121","first-page":"244","article-title":"Cycloserine and isoniazid in childhood tuberculous infections","volume":"7","author":"Schloss","year":"1960","journal-title":"Antibiotic Med Clin Ther (New York)"},{"key":"2026030321351417000_bib122","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0025-7125(16)32984-4","article-title":"Newer and second-line drugs in the treatment of drug-resistant tuberculosis in children","volume":"51","author":"Steiner","year":"1967","journal-title":"Med Clin North Am"},{"key":"2026030321351417000_bib123","first-page":"751","article-title":"Toxicity of cycloserine combined with isoniazid in the treatment of tuberculosis in children","volume":"83","author":"Battaglia","year":"1961","journal-title":"Am Rev Respir Dis"},{"key":"2026030321351417000_bib124","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1473-3099(12)70033-6","article-title":"Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Ettehad","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2026030321351417000_bib125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5588\/ijtld.13.0268","article-title":"Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan","volume":"18","author":"Hung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib126","article-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance","author":"World Health Organization","year":"2014"},{"key":"2026030321351417000_bib127","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026030321351417000_bib128","article-title":"WHO position statement on the use of delamanid for multidrug-resistant tuberculosis","author":"World Health Organization","year":"2018"},{"key":"2026030321351417000_bib129","doi-asserted-by":"crossref","first-page":"1800017","DOI":"10.1183\/13993003.00017-2018","article-title":"Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa","volume":"51","author":"Mohr","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib130","doi-asserted-by":"crossref","first-page":"1701105","DOI":"10.1183\/13993003.01105-2017","article-title":"Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens","volume":"50","author":"Kuksa","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib131","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-2600(18)30455-7","article-title":"Delamanid: does it have a role in tuberculosis treatment?","volume":"7","author":"Centis","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026030321351417000_bib132","doi-asserted-by":"crossref","first-page":"996","DOI":"10.15585\/mmwr.mm6735a6","article-title":"Notes from the field: acquisition of delamanid under a compassionate use program for extensively drug-resistant tuberculosis - United States, 2017","volume":"67","author":"Lardizabal","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026030321351417000_bib133","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1183\/13993003.00705-2016","article-title":"Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib134","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.21037\/jtd.2017.06.16","article-title":"Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review","volume":"9","author":"D\u2019Ambrosio","year":"2017","journal-title":"J Thorac Dis"},{"key":"2026030321351417000_bib135","article-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance","author":"World Health Organization","year":"2016"},{"key":"2026030321351417000_bib136","author":"Dooley"},{"key":"2026030321351417000_bib137","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1183\/13993003.00637-2016","article-title":"First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib138","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1473-3099(18)30100-2","article-title":"Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study","volume":"18","author":"Ferlazzo","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026030321351417000_bib139","doi-asserted-by":"crossref","first-page":"1702467","DOI":"10.1183\/13993003.02467-2017","article-title":"Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea","volume":"51","author":"Kim","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib140","doi-asserted-by":"crossref","first-page":"1800934","DOI":"10.1183\/13993003.00934-2018","article-title":"Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review","volume":"52","author":"Pontali","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib141","article-title":"Pretomanid tablet, 200 mg meeting of the Antimicrobial Drugs Advisory Committee (AMDAC): June 6, 2019","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"2026030321351417000_bib142","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1128\/AAC.00162-09","article-title":"The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis","volume":"53","author":"Goude","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib143","volume-title":"Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children.","author":"Donald","year":"2006"},{"key":"2026030321351417000_bib144","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/cid\/ciu619","article-title":"Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis","volume":"59","author":"Bastos","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib145","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/cid\/ciu572","article-title":"Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis","volume":"59","author":"Cegielski","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib146","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/adc.79.3.274","article-title":"Ethambutol in tuberculosis: time to reconsider?","volume":"79","author":"Graham","year":"1998","journal-title":"Arch Dis Child"},{"key":"2026030321351417000_bib147","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1183\/13993003.00438-2016","article-title":"Efficacy and tolerability of ethionamide versus prothionamide: a systematic review","volume":"48","author":"Scardigli","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib148","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.tube.2015.09.007","article-title":"A review of the use of ethionamide and prothionamide in childhood tuberculosis","volume":"97","author":"Thee","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"2026030321351417000_bib149","doi-asserted-by":"crossref","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"2026030321351417000_bib150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5588\/ijtld.11.0388","article-title":"Ethionamide-induced hypothyroidism","volume":"16","author":"Dutta","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib151","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJM200506303522621","article-title":"Hypothyroidism due to ethionamide","volume":"352","author":"McDonnell","year":"2005","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib152","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.5588\/ijtld.10.0707","article-title":"Abnormal thyroid function tests in children on ethionamide treatment","volume":"15","author":"Thee","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib153","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1128\/AAC.47.12.3799-3805.2003","article-title":"ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates","volume":"47","author":"Morlock","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib154","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature14098","article-title":"A new antibiotic kills pathogens without detectable resistance","volume":"517","author":"Ling","year":"2015","journal-title":"Nature"},{"key":"2026030321351417000_bib155","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases e-book.","author":"Bennett","year":"2014"},{"key":"2026030321351417000_bib156","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkq091","article-title":"Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data","volume":"65","author":"Angeby","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026030321351417000_bib157","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","author":"Peloquin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib158","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1164\/rccm.200308-1159OC","article-title":"Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis","volume":"169","author":"Chan","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib159","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00134712","article-title":"Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes","volume":"42","author":"Falzon","year":"2013","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib160","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/cid\/civ910","article-title":"Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance","volume":"62","author":"Cegielski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib161","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/thoraxjnl-2013-203900","article-title":"High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study","volume":"69","author":"Seddon","year":"2014","journal-title":"Thorax"},{"key":"2026030321351417000_bib162","article-title":"AHFS drug information","author":"American Society of Hospital Pharmacists (AHFS).","year":"2018"},{"key":"2026030321351417000_bib163","article-title":"FDA safety announcement: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"2026030321351417000_bib164","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1542\/peds.2013-3636","article-title":"Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin","volume":"134","author":"Bradley","year":"2014","journal-title":"Pediatrics"},{"key":"2026030321351417000_bib165","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/cid\/ciy416","article-title":"Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis","volume":"67","author":"Garcia-Prats","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib166","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/cid\/cit655","article-title":"Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study","volume":"57","author":"Seddon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib167","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003088-200140001-00005","article-title":"Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers","volume":"40","author":"Stass","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2026030321351417000_bib168","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.1016\/S0002-9343(20)31139-6","article-title":"Pharmacokinetics of gyrase inhibitors, Part 1: basic chemistry and gastrointestinal disposition","volume":"94","author":"S\u00f6rgel","year":"1993","journal-title":"Am J Med"},{"key":"2026030321351417000_bib169","doi-asserted-by":"crossref","first-page":"66S","DOI":"10.1016\/0002-9343(89)90026-0","article-title":"Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule)","volume":"87","author":"Staib","year":"1989","journal-title":"Am J Med"},{"key":"2026030321351417000_bib170","doi-asserted-by":"crossref","first-page":"e01521-17","DOI":"10.1128\/AAC.01521-17","article-title":"Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis","volume":"62","author":"Denti","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib171","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/INF.0000000000001022","article-title":"Pharmacokinetics and dosing of levofloxacin in children treated for active or latent multidrug-resistant tuberculosis, Federated States of Micronesia and republic of the Marshall Islands","volume":"35","author":"Mase","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2026030321351417000_bib172","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/cid\/ciu868","article-title":"Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis","volume":"60","author":"Thee","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib173","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/cid\/ciw483","article-title":"Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: Goldilocks","volume":"63","author":"Srivastava","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib174","doi-asserted-by":"crossref","first-page":"e00770-18","DOI":"10.1128\/AAC.00770-18","article-title":"Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib175","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1086\/499046","article-title":"The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations","volume":"42","author":"Drusano","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib176","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"2026030321351417000_bib177","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics.","author":"Brunton","year":"2018"},{"key":"2026030321351417000_bib178","first-page":"9","article-title":"Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982","volume-title":"J Antimicrob Chemother","author":"Kahlmeter","year":"1984"},{"key":"2026030321351417000_bib179","doi-asserted-by":"crossref","first-page":"e02586-16","DOI":"10.1128\/AAC.02586-16","article-title":"Adverse effects and choice between the injectable agents amikacin and capreomycin in multidrug-resistant tuberculosis","volume":"61","author":"Arnold","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib180","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/jac\/dkr221","article-title":"Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice","volume":"66","author":"Sturdy","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026030321351417000_bib181","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40360-015-0036-7","article-title":"Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort","volume":"16","author":"Sagwa","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026030321351417000_bib182","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jinf.2012.09.002","article-title":"Hearing loss in children treated for multidrug-resistant tuberculosis","volume":"66","author":"Seddon","year":"2013","journal-title":"J Infect"},{"key":"2026030321351417000_bib183","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/INF.0000000000001983","article-title":"Effect of coadministration of lidocaine on the pain and pharmacokinetics of intramuscular amikacin in children with multidrug-resistant tuberculosis: a randomized crossover trial","volume":"37","author":"Garcia-Prats","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2026030321351417000_bib184","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2350-10-2","article-title":"A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness","volume":"10","author":"Bardien","year":"2009","journal-title":"BMC Med Genet"},{"key":"2026030321351417000_bib185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/138161207779313731","article-title":"Aminoglycoside-induced ototoxicity","volume":"13","author":"Selimoglu","year":"2007","journal-title":"Curr Pharm Des"},{"key":"2026030321351417000_bib186","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1517\/14622416.6.1.27","article-title":"Genetic factors in aminoglycoside toxicity","volume":"6","author":"Fischel-Ghodsian","year":"2005","journal-title":"Pharmacogenomics"},{"key":"2026030321351417000_bib187","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/thoraxjnl-2015-207245","article-title":"A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB","volume":"70","author":"Kranzer","year":"2015","journal-title":"Thorax"},{"key":"2026030321351417000_bib188","first-page":"3","article-title":"Prevention and modulation of aminoglycoside ototoxicity (review)","volume":"1","author":"Perletti","year":"2008","journal-title":"Mol Med Rep"},{"key":"2026030321351417000_bib189","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/jac\/dkg249","article-title":"Linezolid in vitro: mechanism and antibacterial spectrum","volume":"51","author":"Livermore","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026030321351417000_bib190","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.diagmicrobio.2008.08.009","article-title":"Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey","volume":"62","author":"Beekmann","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026030321351417000_bib191","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJM200511243532123","article-title":"Mitochondrial toxicity associated with linezolid","volume":"353","author":"Soriano","year":"2005","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib192","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis","volume":"34","author":"Migliori","year":"2009","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib193","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1183\/09031936.00145014","article-title":"Linezolid to treat MDR-\/XDR-tuberculosis: available evidence and future scenarios","volume":"45","author":"Sotgiu","year":"2015","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib194","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1183\/09031936.00191712","article-title":"Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence","volume":"42","author":"Sotgiu","year":"2013","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib195","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib196","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib197","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijantimicag.2017.01.017","article-title":"Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis","volume":"49","author":"Kamp","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2026030321351417000_bib198","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1183\/13993003.02185-2015","article-title":"Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?","volume":"47","author":"Bolhuis","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib199","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tube.2013.10.003","article-title":"Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations","volume":"94","author":"Garcia-Prats","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"2026030321351417000_bib200","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000002093","article-title":"Spanish Paediatric TBRN. Linezolid-containing treatment regimens for tuberculosis in children","author":"Prieto","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2026030321351417000_bib201","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1128\/AAC.49.9.3896-3902.2005","article-title":"Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis","volume":"49","author":"Nagiec","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib202","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1093\/cid\/ciy625","article-title":"Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment","volume":"67","author":"Bolhuis","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib203","doi-asserted-by":"crossref","first-page":"e00751-17","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib204","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"key":"2026030321351417000_bib205","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: a review of safety and tolerability","volume":"59","author":"Vinh","year":"2009","journal-title":"J Infect"},{"key":"2026030321351417000_bib206","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib207","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1128\/AAC.00264-06","article-title":"Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible","volume":"50","author":"Andini","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib208","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1128\/AAC.47.10.3053-3060.2003","article-title":"Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38)","volume":"47","author":"Nash","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib209","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1128\/AAC.39.12.2827","article-title":"Clarithromycin is inactive against Mycobacterium tuberculosis","volume":"39","author":"Truffot-Pernot","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib210","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1183\/09031936.00001913","article-title":"Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients","volume":"42","author":"Bolhuis","year":"2013","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib211","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1183\/09031936.00147014","article-title":"Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis","volume":"46","author":"van der Paardt","year":"2015","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib212","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0140-6736(46)91185-3","article-title":"Para-aminosalicylic acid in the treatment of tuberculosis","volume":"1","author":"Lehmann","year":"1946","journal-title":"Lancet"},{"key":"2026030321351417000_bib213","doi-asserted-by":"crossref","first-page":"23447","DOI":"10.1074\/jbc.M113.475798","article-title":"para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis","volume":"288","author":"Zheng","year":"2013","journal-title":"J Biol Chem"},{"key":"2026030321351417000_bib214","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJM195201242460404","article-title":"Effect of combined therapy (dihydrostreptomycin and PAS) on the emergence of streptomycin-resistant strains of tubercle bacilli","volume":"246","author":"Shane","year":"1952","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00000441-195207000-00008","article-title":"The effect of para-aminosalicylic acid (PAS) on the development of resistance of tubercle bacilli to streptomycin","volume":"224","author":"Friedman","year":"1952","journal-title":"Am J Med Sci"},{"key":"2026030321351417000_bib216","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1473-3099(15)00263-7","article-title":"Para-aminosalicylic acid: the return of an old friend","volume":"15","author":"Donald","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026030321351417000_bib217","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S1473-3099(18)30073-2","article-title":"Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study","volume":"18","author":"Zignol","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026030321351417000_bib218","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","article-title":"Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","volume":"16","author":"Zignol","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026030321351417000_bib219","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1128\/AAC.00632-16","article-title":"Pyrazinamide resistance assays and two-month sputum culture status in patients with multidrug-resistant tuberculosis","volume":"60","author":"Vel\u00e1squez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.advms.2015.09.007","article-title":"Pyrazinamide resistance in Mycobacterium tuberculosis: review and update","volume":"61","author":"Njire","year":"2016","journal-title":"Adv Med Sci"},{"key":"2026030321351417000_bib221","doi-asserted-by":"crossref","first-page":"1702292","DOI":"10.1183\/13993003.02292-2017","article-title":"Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens","volume":"50","author":"Cabibbe","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib222","doi-asserted-by":"crossref","first-page":"1701354","DOI":"10.1183\/13993003.01354-2017","article-title":"A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis","volume":"50","author":"Miotto","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib223","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the british medical research council tuberculosis units, 1946-1986, with relevant subsequent publications","volume-title":"Int J Tuberc Lung Dis","author":"Fox","year":"1999"},{"key":"2026030321351417000_bib224","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1378\/chest.94.4.845","article-title":"The role of pyrazinamide in tuberculosis chemotherapy","volume":"94","author":"Steele","year":"1988","journal-title":"Chest"},{"key":"2026030321351417000_bib225","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib226","doi-asserted-by":"crossref","first-page":"1600803","DOI":"10.1183\/13993003.00803-2016","article-title":"An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis","volume":"49","author":"Bastos","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib227","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1164\/rccm.201112-2174ED","article-title":"Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence","volume":"185","author":"Saukkonen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib228","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-3099(16)30538-2","article-title":"Resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: authors\u2019 reply","volume":"17","author":"Zignol","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2026030321351417000_bib229","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMsr1512438","article-title":"Twenty years of global surveillance of antituberculosis-drug resistance","volume":"375","author":"Zignol","year":"2016","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib230","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa1800474","article-title":"Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing","volume":"379","author":"Allix-B\u00e9guec","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib231","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1093\/cid\/ciy710","article-title":"The role of novel approaches and new findings in the pharmacology of tuberculosis medicines in improving treatment outcomes","volume":"67","author":"Falzon","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib232","doi-asserted-by":"crossref","first-page":"e01695-18","DOI":"10.1128\/AAC.01695-18","article-title":"Effect of moxifloxacin plus pretomanid against Mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay","volume":"63","author":"de Miranda Silva","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib233","doi-asserted-by":"crossref","first-page":"e00856-18","DOI":"10.1128\/AAC.00856-18","article-title":"Effect of linezolid plus bedaquiline against mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay","volume":"62","author":"de Miranda Silva","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib234","doi-asserted-by":"crossref","first-page":"e00636-18","DOI":"10.1128\/AAC.00636-18","article-title":"Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis","volume":"62","author":"Ammerman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib235","doi-asserted-by":"crossref","first-page":"eaau0965","DOI":"10.1126\/scitranslmed.aau0965","article-title":"Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis","volume":"10","author":"Tucker","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026030321351417000_bib236","doi-asserted-by":"crossref","DOI":"10.3791\/57402","article-title":"Spatial quantification of drugs in pulmonary tuberculosis lesions by laser capture microdissection liquid chromatography mass spectrometry (LCM-LC\/MS)","author":"Zimmerman","year":"2018","journal-title":"J Vis Exp"},{"key":"2026030321351417000_bib237","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1128\/AAC.00115-15","article-title":"A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets","volume":"59","author":"Via","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib238","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib239","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials","volume":"102","author":"Savic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026030321351417000_bib240","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/cid\/ciy026","article-title":"The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis","volume":"67","author":"Svensson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib241","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"2026030321351417000_bib242","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0029-2016","article-title":"The role of therapeutic drug monitoring in mycobacterial infections","volume":"5","author":"Peloquin","year":"2017","journal-title":"Microbiol Spectr"},{"key":"2026030321351417000_bib243","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1093\/cid\/ciy608","article-title":"Pharmacokinetic\/pharmacodynamic background and methods and scientific evidence base for dosing of second-line tuberculosis drugs","volume":"67","author":"Gumbo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib244","article-title":"Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis","author":"Lange","journal-title":"J Intern Med"},{"key":"2026030321351417000_bib245","doi-asserted-by":"crossref","first-page":"e01400-16","DOI":"10.1128\/AAC.01400-16","article-title":"Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis","volume":"61","author":"van Altena","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib246","doi-asserted-by":"crossref","first-page":"S308","DOI":"10.1093\/cid\/ciy624","article-title":"D-cycloserine pharmacokinetics\/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: a Faustian deal","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib247","doi-asserted-by":"crossref","first-page":"e01741-e15","DOI":"10.1128\/mBio.01741-15","article-title":"Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy","volume":"6","author":"Brown","year":"2015","journal-title":"MBio"},{"key":"2026030321351417000_bib248","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40265-018-1043-y","article-title":"The role of fluoroquinolones in the treatment of tuberculosis in 2019","volume":"79","author":"Pranger","year":"2019","journal-title":"Drugs"},{"key":"2026030321351417000_bib249","doi-asserted-by":"crossref","first-page":"1700061","DOI":"10.1183\/13993003.00061-2017","article-title":"Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses","volume":"50","author":"Ahmad","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5588\/ijtld.17.0498","article-title":"Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries","volume":"22","author":"Tr\u00e9bucq","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib251","doi-asserted-by":"crossref","first-page":"e014386","DOI":"10.1136\/bmjopen-2016-014386","article-title":"Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol","volume":"6","author":"Gama","year":"2016","journal-title":"BMJ Open"},{"key":"2026030321351417000_bib252","first-page":"926","article-title":"48th Union World Conference on Lung Health","volume-title":"Lancet Respir Med","author":"Akkermans","year":"2017"},{"key":"2026030321351417000_bib253","author":"World Health Organization"},{"key":"2026030321351417000_bib254","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1164\/rccm.201606-1097LE","article-title":"Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe","volume":"194","author":"Lange","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib255","doi-asserted-by":"crossref","first-page":"1702267","DOI":"10.1183\/13993003.02267-2017","article-title":"Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico","volume":"50","author":"Munoz-Torrico","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib256","first-page":"ciz263","article-title":"Eligibility for a shorter treatment regimen for multidrug-resistant tuberculosis in the United States, 2011-2016","author":"Tsang","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib257","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201701-0013LE","article-title":"Benefit of the shorter multidrug-resistant tuberculosis treatment regimen in California and modified eligibility criteria","volume":"196","author":"Barry","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib258","doi-asserted-by":"crossref","first-page":"e0119628","DOI":"10.1371\/journal.pone.0119628","article-title":"Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review","volume":"10","author":"Seifert","year":"2015","journal-title":"PLoS One"},{"key":"2026030321351417000_bib259","doi-asserted-by":"crossref","first-page":"1700223","DOI":"10.1183\/13993003.00223-2017","article-title":"Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance","volume":"49","author":"Van Deun","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib260","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/JCM.02724-12","article-title":"Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs","volume":"51","author":"Horne","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2026030321351417000_bib261","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1128\/JCM.06479-11","article-title":"Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008","volume":"50","author":"Angra","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2026030321351417000_bib262","article-title":"DR-TB clinical trials progress report","author":"Resist-TB","year":"2018"},{"key":"2026030321351417000_bib263","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5588\/ijtld.12.0198","article-title":"Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"17","author":"Marrone","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib264","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MCP.0b013e3282f76417","article-title":"Surgery for pulmonary tuberculosis","volume":"14","author":"Naidoo","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"2026030321351417000_bib265","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1067\/mtc.2001.112339","article-title":"Pulmonary resection for multi-drug resistant tuberculosis","volume":"121","author":"Pomerantz","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026030321351417000_bib266","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1052-3359(25)00476-4","article-title":"History of resectional surgery for tuberculosis and other mycobacterial infections","volume":"10","author":"Pomerantz","year":"2000","journal-title":"Chest Surg Clin N Am"},{"key":"2026030321351417000_bib267","article-title":"The role of surgery in the treatment of pulmonary tb and multidrug-and extensively drug-resistant tb","author":"World Health Organization","year":"2014"},{"key":"2026030321351417000_bib268","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.thorsurg.2012.05.003","article-title":"The history of surgery for pulmonary tuberculosis","volume":"22","author":"Odell","year":"2012","journal-title":"Thorac Surg Clin"},{"key":"2026030321351417000_bib269","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/ejcts\/ezv228","article-title":"A retrospective review comparing treatment outcomes of adjuvant lung resection for drug-resistant tuberculosis in patients with and without human immunodeficiency virus co-infection","volume":"49","author":"Alexander","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026030321351417000_bib270","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1183\/09031936.00229514","article-title":"Untreatable tuberculosis: is surgery the answer?","volume":"45","author":"Dara","year":"2015","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib271","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/cid\/ciw002","article-title":"Surgery as an adjunctive treatment for multidrug-resistant tuberculosis: an individual patient data metaanalysis","volume":"62","author":"Fox","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib272","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12879-016-1585-0","article-title":"The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"16","author":"Harris","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2026030321351417000_bib273","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jinf.2018.08.003","article-title":"Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery","volume":"78","author":"Borisov","year":"2019","journal-title":"J Infect"},{"key":"2026030321351417000_bib274","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","article-title":"Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis","volume":"17","author":"Gegia","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2026030321351417000_bib275","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib276","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","article-title":"Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis","volume":"6","author":"Fregonese","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026030321351417000_bib277","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib278","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1128\/AAC.01621-06","article-title":"Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin","volume":"51","author":"Weiner","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib279","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib280","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid: Tuberculosis Trials Consortium","volume":"353","author":"Vernon","year":"1999","journal-title":"Lancet"},{"key":"2026030321351417000_bib281","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1164\/ajrccm.153.2.8564140","article-title":"Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS","volume":"153","author":"Lutfey","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321351417000_bib282","doi-asserted-by":"crossref","first-page":"969","DOI":"10.5588\/ijtld.15.0123","article-title":"Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis","volume":"19","author":"Isaakidis","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib283","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5588\/ijtld.11.0153","article-title":"Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting","volume":"16","author":"Gandhi","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib284","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3201\/eid2005.131037","article-title":"Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007","volume":"20","author":"Marks","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2026030321351417000_bib285","article-title":"WHO policy on collaborative TB\/HIV activities: guidelines for national programmes and other stakeholders","author":"World Health Organization","year":"2012"},{"key":"2026030321351417000_bib286","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib287","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib288","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib289","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/cid\/ciu094","article-title":"Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Masur","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib290","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5588\/ijtld.13.0627","article-title":"Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial","volume":"18","author":"Padayatchi","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib291","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5588\/ijtld.11.0473","article-title":"HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era","volume":"16","author":"Palacios","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib292","doi-asserted-by":"crossref","first-page":"e47370","DOI":"10.1371\/journal.pone.0047370","article-title":"Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review","volume":"7","author":"Arentz","year":"2012","journal-title":"PLoS One"},{"key":"2026030321351417000_bib293","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/S0140-6736(10)60492-8","article-title":"Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study","volume":"375","author":"Dheda","year":"2010","journal-title":"Lancet"},{"key":"2026030321351417000_bib294","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3201\/eid1903.120998","article-title":"Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection","volume":"19","author":"O\u2019Donnell","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"2026030321351417000_bib295","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/QAI.0b013e31821190a3","article-title":"Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients","volume":"57","author":"Kvasnovsky","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026030321351417000_bib296","doi-asserted-by":"crossref","first-page":"e46943","DOI":"10.1371\/journal.pone.0046943","article-title":"Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho","volume":"7","author":"Satti","year":"2012","journal-title":"PLoS One"},{"key":"2026030321351417000_bib297","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(13)62675-6","article-title":"Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study","volume":"383","author":"Pietersen","year":"2014","journal-title":"Lancet"},{"key":"2026030321351417000_bib298","doi-asserted-by":"crossref","first-page":"c4451","DOI":"10.1136\/bmj.c4451","article-title":"Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study","volume":"341","author":"Vinnard","year":"2010","journal-title":"BMJ"},{"key":"2026030321351417000_bib299","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1128\/AAC.00319-12","article-title":"Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis","volume":"56","author":"Tho","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/cid\/ciw763","article-title":"Long-term mortality of patients with tuberculous meningitis in New York City: a cohort study","volume":"64","author":"Vinnard","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib301","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib302","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV): associated tuberculous meningitis","volume":"52","author":"T\u00f6r\u00f6k","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib303","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1128\/AAC.00509-16","article-title":"Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects","volume":"60","author":"Mallikaarjun","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321351417000_bib304","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM199603143341106","article-title":"Physicians\u2019 experience with the acquired immunodeficiency syndrome as a factor in patients\u2019 survival","volume":"334","author":"Kitahata","year":"1996","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib305","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-156-11-201206050-00419","article-title":"Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel","volume":"156","author":"Thompson","year":"2012","journal-title":"Ann Intern Med"},{"key":"2026030321351417000_bib306","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(14)70245-1","article-title":"Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study","volume":"2","author":"Dodd","year":"2014","journal-title":"Lancet Glob Health"},{"key":"2026030321351417000_bib307","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(16)30474-1","article-title":"Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis","volume":"17","author":"Jenkins","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2026030321351417000_bib308","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(16)30132-3","article-title":"Global burden of drug-resistant tuberculosis in children: a mathematical modelling study","volume":"16","author":"Dodd","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026030321351417000_bib309","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0140-6736(14)60195-1","article-title":"Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates","volume":"383","author":"Jenkins","year":"2014","journal-title":"Lancet"},{"key":"2026030321351417000_bib310","doi-asserted-by":"crossref","first-page":"S593","DOI":"10.5588\/ijtld.17.0355","article-title":"Pharmacokinetics, safety and optimal dosing of linezolid in children with multidrug-resistant tuberculosis","volume":"22","author":"Garcia-Prats","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib311","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QCO.0000000000000062","article-title":"Managing multidrug-resistant tuberculosis in children: review of recent developments","volume":"27","author":"Schaaf","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"2026030321351417000_bib312","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12884-016-1096-4","article-title":"Pregnancy in patients with tuberculosis: a TBNET cross-sectional survey","volume":"16","author":"Bothamley","year":"2016","journal-title":"BMC Pregnancy Childbirth"},{"key":"2026030321351417000_bib313","first-page":"637","article-title":"Multidrug-resistant tuberculosis in pregnancy","volume":"17","author":"K","year":"2007","journal-title":"J Coll Physicians Surg Pak"},{"key":"2026030321351417000_bib314","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1590\/S0037-86822011000500020","article-title":"Characterization of multidrug-resistant tuberculosis during pregnancy in Campinas, State of S\u00e3o Paulo, Brazil, from 1995 to 2007 [in Portuguese]","volume":"44","author":"Oliveira","year":"2011","journal-title":"Rev Soc Bras Med Trop"},{"key":"2026030321351417000_bib315","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1086\/598191","article-title":"Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru","volume":"48","author":"Palacios","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib316","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/374225","article-title":"Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases","volume":"36","author":"Shin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib317","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s15010-007-6318-2","article-title":"Multi-drug resistant tuberculosis in pregnancy: need for more intensive treatment","volume":"35","author":"Tabarsi","year":"2007","journal-title":"Infection"},{"key":"2026030321351417000_bib318","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5588\/ijtld.10.0140","article-title":"Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy","volume":"15","author":"Tabarsi","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib319","first-page":"413","article-title":"Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy [in Japanese]","volume":"81","author":"Takashima","year":"2006","journal-title":"Kekkaku"},{"key":"2026030321351417000_bib320","doi-asserted-by":"crossref","DOI":"10.3201\/eid2310.161398","article-title":"Bedaquiline and linezolid for extensively drug-resistant tuberculosis in pregnant woman","volume":"23","author":"Jaspard","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2026030321351417000_bib321","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1378\/chest.123.3.953","article-title":"Multidrug-resistant tuberculosis in pregnancy: case report and review of the literature","volume":"123","author":"Lessnau","year":"2003","journal-title":"Chest"},{"key":"2026030321351417000_bib322","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/514795","article-title":"Management of four pregnant women with multidrug-resistant tuberculosis","volume":"28","author":"Nitta","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib323","first-page":"67","article-title":"A successfully treated severe case of extensively drug-resistant tuberculosis during pregnancy","author":"\u00dcnl\u00fc","year":"2015"},{"key":"2026030321351417000_bib324","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/01.idc.0000078749.71576.0d","article-title":"New challenges in the clinical management of drug-resistant tuberculosis","volume":"11","author":"Mukherjee","year":"2002","journal-title":"Infect Dis Clin Pract"},{"key":"2026030321351417000_bib325","first-page":"706","article-title":"Pregnancies complicated by multidrug-resistant tuberculosis and HIV co-infection in Durban, South Africa","volume":"11","author":"Khan","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib326","first-page":"1536281","article-title":"Multidrug-resistant tuberculosis during pregnancy: two case reports and review of the literature","volume":"2016","author":"Rohilla","year":"2016","journal-title":"Case Rep Obstet Gynecol"},{"key":"2026030321351417000_bib327","doi-asserted-by":"crossref","first-page":"1601724","DOI":"10.1183\/13993003.01724-2016","article-title":"Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis","volume":"49","author":"Van Kampenhout","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib328","article-title":"Pregnancy, lactation, and reproductive potential: labeling for human prescription drug and biological products\u2014content and format. Guidance for industry","author":"U.S. Food and Drug Administration","year":"2014"},{"key":"2026030321351417000_bib329","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.21037\/jtd.2018.05.11","article-title":"Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill","volume":"10","author":"Esmail","year":"2018","journal-title":"J Thorac Dis"},{"key":"2026030321351417000_bib330","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/cid\/civ991","article-title":"Toward earlier inclusion of pregnant and postpartum women in tuberculosis drug trials: consensus statements from an international expert panel","volume":"62","author":"Gupta","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib331","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"American Thoracic Society","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"2026030321351417000_bib332","first-page":"61","article-title":"Management of persons exposed to multidrug-resistant tuberculosis","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"2026030321351417000_bib333","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/cix208","article-title":"Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis","volume":"64","author":"Marks","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026030321351417000_bib334","author":"Seddon","year":"2015","journal-title":"Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations."},{"key":"2026030321351417000_bib335","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.13.0028","article-title":"Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012","volume":"18","author":"Bamrah","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib336","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.5588\/ijtld.12.0092","article-title":"Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995-2010","volume":"16","author":"Denholm","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321351417000_bib337","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/INF.0000000000000260","article-title":"Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis","volume":"33","author":"Adler-Shohet","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2026030321351417000_bib338","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/INF.0b013e31829157e9","article-title":"Management of pediatric contacts of multidrug resistant tuberculosis in the United Kingdom","volume":"32","author":"Williams","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2026030321351417000_bib339","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1542\/peds.109.5.765","article-title":"Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up","volume":"109","author":"Schaaf","year":"2002","journal-title":"Pediatrics"},{"key":"2026030321351417000_bib340","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM199404283301718","article-title":"Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis","volume":"330","author":"Horn","year":"1994","journal-title":"N Engl J Med"},{"key":"2026030321351417000_bib341","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis","volume":"167","author":"Papastavros","year":"2002","journal-title":"CMAJ"},{"key":"2026030321351417000_bib342","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/09031936.05.00006205","article-title":"High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis","volume":"26","author":"Younossian","year":"2005","journal-title":"Eur Respir J"},{"key":"2026030321351417000_bib343","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1201\/b16604-13","article-title":"Clinical pharmacology of the anti-tuberculosis drugs","volume-title":"Clinical tuberculosis","author":"Alsultan","year":"2014"},{"key":"2026030321351417000_bib344","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1472-9792(08)70002-7","article-title":"Handbook of anti-tuberculosis agents: introduction","volume":"88","year":"2008","journal-title":"Tuberculosis (Edinb)"}],"updated-by":[{"DOI":"10.1164\/rccm.v201erratum2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000}}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/200\/10\/e93\/67170450\/ajrccm_200_10_e93.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/200\/10\/e93\/67170450\/ajrccm_200_10_e93.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:35:53Z","timestamp":1772591753000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/200\/10\/e93\/8497038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":344,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,11,15]]},"published-print":{"date-parts":[[2019,11,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201909-1874st","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"2019-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}